Axel Bolte - 24 Feb 2022 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Chief Executive Officer, Director
Signature
/s/ Axel Bolte
Issuer symbol
INZY
Transactions as of
24 Feb 2022
Net transactions value
$0
Form type
4
Filing time
28 Feb 2022, 06:47:46 UTC
Previous filing
25 Jun 2021
Next filing
20 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Stock option (right to buy) Award $0 +275,000 $0.000000 275,000 24 Feb 2022 Common Stock 275,000 $5.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 24, 2022. The shares underlying the option are scheduled to vest in equal monthly installments from February 24, 2022 through February 24, 2026.